论文部分内容阅读
目的探讨埃索美拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡(Hp)的疗效观察。方法收集68例Hp阳性的消化性溃疡患者,随机分为治疗组与对照组,每组均为34例。治疗组患者予以埃索美拉唑、阿莫西林和克拉霉素三联治疗,对照组予以雷尼替丁、阿莫西林和克拉霉素三联治疗。两组患者治疗4周后,观察临床症状改善,并通过内镜检查,观察溃疡愈合及Hp清除,并比较胃窦部炎症情况。结果两组患者治疗前临床症状比较无明显统计学差异(P>0.05)。治疗组患者治疗4周后临床症状如上腹部疼痛、上腹部不适、嗳气等均得到有效控制(P<0.01),而对照组仅上腹部疼痛的症状得到控制(P<0.01),上腹部不适、嗳气等症状无明显改善(P>0.05)。治疗组患者治疗4周后Hp清除率和溃疡愈合率均明显高于对照组(P<0.01),且治疗组胃窦部黏膜炎症程度明显低于对照组(P<0.05)。结论埃索美拉唑能迅速有效缓解消化性溃疡的症状,促进溃疡愈合,并能有效根除Hp感染,具有良好的应用前景。
Objective To investigate the efficacy of esomeprazole triple therapy in the treatment of Helicobacter pylori-associated peptic ulcer (Hp). Methods Sixty-eight Hp-positive peptic ulcer patients were randomly divided into treatment group and control group, with 34 cases in each group. The patients in the treatment group were treated with esomeprazole, amoxicillin and clarithromycin triple therapy, and the control group ranitidine, amoxicillin and clarithromycin triple therapy. After 4 weeks of treatment, the clinical symptoms were observed and the ulcer healing and Hp clearance were observed by endoscopy. The inflammation of gastric antrum was also compared. Results There was no significant difference in clinical symptoms between the two groups before treatment (P> 0.05). After 4 weeks of treatment, the clinical symptoms such as upper abdominal pain, upper abdominal discomfort and belching were effectively controlled (P <0.01), while the control group only controlled the symptoms of upper abdominal pain (P0.01), upper abdominal discomfort, Qi and other symptoms no significant improvement (P> 0.05). After 4 weeks of treatment, the Hp clearance rate and ulcer healing rate were significantly higher in the treatment group than those in the control group (P <0.01). The degree of antral mucosal inflammation in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion Esomeprazole can effectively relieve the symptoms of peptic ulcer, accelerate the healing of ulcer and effectively eradicate Hp infection, which has a good prospect of application.